A COVID-19 Curing Pill


Wikimedia Commons

Covid-19 vaccine being loaded into an shot.

Over the chaos of the ever-spreading COVID-19 virus, the biopharmaceutical company, Pfizer, has been setting tests to invent an effective oral antiviral drug in the form of a pill. To keep people out of the hospital, scientists suggest oral therapy, which would help “eliminate many of the barriers to treatment.” Even though several successful vaccines prevent the virus while the person isn’t infected, it is much more complex and takes longer to treat those already infected. The drugs available to infected patients can trigger other side effects that could be worse for the patient and keep them hospitalized longer.

This pill that could halt COVID early in its tracks has already been tested in Seattle’s Fred Hutch cancer research center. Miranda and Joe Kelly fell ill with the virus in June of 2021 and agreed to join their clinical trial. They received their medication and had started taking the pills four twice a day. A week into taking the drugs, their symptoms improved, but they were not completely recovered. Within two weeks, the couple discovered their symptoms were gone, and by this time, were believed to have recovered completely. Dr. Daniel Griffin says the antiviral pills would be no substitute for the vaccination, but “it’s nice to have another option.”

Last spring, the pill had also been given to people who signed up to be in the clinical trials of the research centers. Two hundred and two patients signed up and noticed how fast the pills allowed them to recover. The pills have been proven to help with the side effects and symptoms of the virus, and within two weeks or so, patients confirmed they were feeling much better and were clear of all COVID-related symptoms. Robert Davis, a Merck chief executive, states that “this month the company expects data from its larger phase 3 trials in the coming weeks.” On September 1, 2021, Pfizer launched its product’s “combined phase 2 and 3 trial”. The results of these phases are said to be expected later on this year, as confirmed by Atea officials. Carl Dieffenbach, director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, says that “if the results are positive and emergency use is granted for any product, the distribution could begin quickly.”

To conclude, we might be able to see many quick recoveries and successful treatments to help with the battle of the COVID-19 pandemic as soon as this year.